Cost-effectiveness analysis of adjuvant atezolizumab in stage II-IIIA non-small cell lung cancer expressing ≥50% PD-L1: A United Kingdom health care perspective
- Resource Type
- Article
- Source
- In
Lung Cancer May 2023 179 - Subject
- Language
- ISSN
- 0169-5002